SecBot SecBot
8-K ·Filed Nov 12, 2026

GENB

Generate Biomedicines, Inc.
BEARISH
Impact 5/10
Horizonmonths Processed4d 19h ago SEC0001193125-26-456921
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The revenue decline reflects near-completion of Amgen and Novartis collaboration obligations, creating a revenue gap. Watch for new partnership announcements to replace this revenue stream and for Phase 3 SOLAIRIA data readouts for GB-0895, which is the key pipeline catalyst.

DirectionBearish
Confidencehigh
Horizonmonths

Drugs in focus

GENB drug pipeline →

GB-0895

▲ Bullish Named in this 8-K
Impact
Phase
Phase 3
Time to market
Estimated at 2-4 years assuming successful completion of the ongoing Phase 3 trials, regulatory filing, and FDA review.
Next catalyst
None dated

What to watchGB-0895 is the lead asset driving essentially all of GENB's valuation. Watch for updates on SOLAIRIA-1 and SOLAIRIA-2 enrollment completion and any disclosed Phase 3 topline timeline, as that will be the next major binary event. Also monitor Tezspire's (tezepelumab) commercial trajectory and label expansion, as it is the direct competitor and its performance sets market expectations for TSLP-targeting therapies. The Zealand Pharma partnership provides non-dilutive cash but is early-stage and adds no near-term revenue.

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$12.57
T+0 close · Nov 12, 2026 · via day close
Latest settled
−3.98%
T+1 · $12.07
Vs SPY
−3.61%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $12.57entry
  2. T+1 · 4d ago −3.98%α −3.61% · $12.07
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Generate Biomedicines reported Q3 2026 collaboration revenue of $4.2M (down 56% YoY from $9.6M) and a net loss of $87.7M (widened from $60.0M), both worse than consensus. The company highlighted clinical progress across its pipeline and a new Zealand Pharma collaboration providing $30M upfront, but the revenue decline and growing operating loss overshadow the operational updates.

Key Financial Metrics

Revenue
$4.2M
est $7.8M · -46.1% · -56.2% YoY

Key Facts

  • Q3 2026 collaboration revenue was $4.2 million, down 56% from $9.6 million in Q3 2025
  • Net loss was $87.7 million, compared to $60.0 million in Q3 2025
  • Cash, cash equivalents and marketable securities were $404.2 million as of Sept. 30, 2026
  • Zealand Pharma collaboration provides $30 million upfront and up to $35 million in early preclinical milestones
  • GB-0895 Phase 3 SOLAIRIA studies in severe asthma are ongoing; Phase 1b COPD data showed sustained biomarker suppression for at least six months
  • GB-4362 advanced to second dose-escalation cohort in advanced urothelial cancer
  • First patient dosed in GB-5267 Phase 1 study in platinum-resistant ovarian cancer
  • Anthropic collaboration announced for AI-driven CAR T-cell research

Financial Impact

Revenue declined 56% YoY to $4.2M; net loss widened to $87.7M; EPS miss of 23.6% vs consensus

revenuenet lossepscash burn

Risk Factors

  • Revenue is declining as existing collaboration programs near completion
  • Operating expenses continue to rise, driving deeper net losses and cash burn
  • No consensus-beating financial results; EPS missed by 23.6%
  • Cash runway only into first half of 2028, requiring additional capital for long-term operations

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-456921
Document: ck0002100782-20261112.htm0001193125-26-456921
Document: 0001193125-26-456921-index-headers.html0001193125-26-456921
Document: 0001193125-26-456921-index.html0001193125-26-456921
Document: 0001193125-26-456921.txt0001193125-26-456921
8-K Data (Synthetic)0001193125-26-456921

Track record

11 reports on GENB

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +14.28% at T+20 after the Oct 1, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Bearish 5/10 Viewing Entry $12.57 Now $10.49 +16.55% settles Dec 11
  2. Nov 5, 202611d ago SC 13G Neutral 3/10 Entry $12.57 Now $10.49 −16.55% settles Dec 4
  3. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $13.85 Now $10.49 −24.26% settles Dec 2
  4. Oct 29, 202618d ago 144 Neutral 2/10 Entry $14.46 Now $10.49 −27.46% settles Nov 30
  5. Oct 13, 20264w ago Press Release Bullish 6/10 Entry $12.52 to $13.49 Now $10.49 −16.21% ▲ +7.75% +9.02% vs SPY
  6. Oct 1, 20266w ago Press Release Bullish 5/10 Entry $13.80 to $15.77 Now $10.49 −23.99% ▲ +14.28% +13.57% vs SPY
  7. May 7, 202627w ago 8-K Bearish 6/10 Entry $13.59 to $12.91 Now $10.49 +22.81% ▲ +5.00% +8.14% vs SPY
  8. Mar 2, 202637w ago Insider Cluster Bullish 7/10 Entry $11.93 to $12.50 Now $10.49 −12.07% ▲ +4.78% +9.19% vs SPY
  9. Mar 2, 202637w ago Insider Cluster Neutral 3/10 Entry $11.93 to $12.50 Now $10.49 −12.07% ▲ +4.78% +9.19% vs SPY
  10. Feb 27, 202637w ago 424B4 Bearish 7/10 Entry $12.17 to $11.51 Now $10.49 +13.80% ▲ +5.42% −2.52% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 7h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026